Analyst Nico Chen from DBS maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at $900.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Nico Chen has given his Buy rating due to a combination of factors that highlight Eli Lilly & Co’s promising growth prospects. One significant reason is the company’s strong pipeline, particularly the anticipated revenue growth acceleration from a compound annual growth rate of 11.6% to 27.2% in the upcoming three years. This growth is driven by the potential approval of promising drugs like Orforglipron, which is in Phase 3 trials and expected to boost the share price due to its efficacy in weight loss treatments.
Nico Chen also notes the success of Eli Lilly’s existing products in the weight-loss segment, such as Mounjaro and Zepbound, which have significantly contributed to the company’s revenue. Additionally, the strong market performance of these drugs has been bolstered by their clinical superiority over competitors, as demonstrated in trials. Despite potential risks such as the expiry of key patents like Trulicity in 2027, the current catalysts and robust pipeline underpin the positive outlook, supporting the Buy rating with a target price of USD 900.
In another report released on February 13, Citi also maintained a Buy rating on the stock with a $1,190.00 price target.
Based on the recent corporate insider activity of 133 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLY in relation to earlier this year.